1. Title: Clinical study of the relationship between Pharmacogenomics and warfarin dose in Chinese patients 2. Drug: Warfarin 3. Design: To value the accuracy of warfarin Pharmacogenomics algorithm by the algorithm calculated dose and actual dose in the Chinese patients. 4. Hypothesis:Pharmacogenomic algorithm guided dose can help to predict warfarin dose in Chinese patients.
* For the patients who need to use warfarin, detect the "Vitamin K epoxide reductase complex subunit 1 (VKORC1),cytochrome p450 2C9 (CYP2C9), and cytochrome p450 4F2 (CYP4F2) genotype. * Record the demographic information: gender, age, height, and weight. * Record drug combination, complications, and international normalized ratio (INR), liver function and kidney function or other biochemical test results. * Put genotypes, demographic information and other clinical information into the algorithm to calculate warfarin dose for the patients, and compared with the actual dose.
Study Type
OBSERVATIONAL
Enrollment
1,000
Prescribe warfarin to the patients who are needed.
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
RECRUITINGThe accuracy of the pharmacogenomics algorithm for warfarin maintenance dose
The proportion of the patients whose predicted dose were within 20% of the actual maintenance dose.
Time frame: one month after the initial dose of warfarin
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.